G.F.W. received grants or honoraria from Amgen, Novartis, Arrowhead, Esperion, AstraZeneca, Pfizer, Novo Nordisk, Silence Therapeutics, CSL Seqirus, and Sanofi-Regeneron. R.A.H. served on advisory boards for Acasti, Akcea-Ionis, Amgen, Arrowhead, HLS Therapeutics, Medison, Novartis, Pfizer, Sanofi, Regeneron, and UltraGenyx, and has received honoraria for continuing medical education talks from Amgen, HLS Therapeutics, Novartis, and Pfizer. R.S.R. reports research funding to his institution from Amgen, Arrowhead, Eli Lilly, Merck, National Institutes of Health, Novartis, Novo Nordisk, and 89Bio; consulting fees from Amgen, Arrowhead, CRISPR Therapeutics, Editas Medicine, Eli Lilly, Intercept Pharmaceuticals, Life Extension, Lipigon, New Amsterdam, Novartis, Organon, Precision Biosciences, Regeneron, Rona Therapeutics, UltraGenyx, and Verve Therapeutics; nonpromotional honoraria from Kowa America Corporation and Viatris; royalties from Wolters Kluwer (UpToDate); and stock holding in MediMergent, LLC. R.S.R. also reports patent applications on “Methods and systems for biocellular marker detection and diagnosis using a microfluidic profiling device,” United States Patent & Trademark Office (USPTO) Electronic Filing System ID, 32278349, application No. PCT/US2019/026364 (provisional); and “Compositions and methods relating to the identification and treatment of immunothrombotic conditions,” new international USPTO application No. PCT/US2021/63104926. I.J.G. received research funding (grant numbers HL45095, 160891, 151328, and 160470) from the National Heart, Lung, and Blood Institute. I.J.G. has also received funds as a consultant to Arrowhead Pharmaceuticals. A.G. received funding from Amgen, Arrowhead, Bio89, Ionis, and Sanofi-Regeneron. A.G. has also received honoraria for boards, conferences, or congresses from Akcea, Amarin, Amgen, AstraZeneca, Chiesi, Lilly, Merck Sharp & Dohme, Novartis, Sanofi-Regeneron, Servier, Viatris, and Ultragenyx. A.B. received research grants from Akcea, Amgen, Astra Zeneca, Foundation Leducq, Foundation Yvan Morin, Merck Frosst, and Sanofi and has participated in clinical research protocols from Acasti Pharma Inc, Akcea, Amgen, Arrowhead Pharmaceuticals, Astra Zeneca, Ionis Pharmaceuticals, Inc, Isis Pharmaceuticals, The Medicines Company, Merck Frosst, Novartis, Pfizer, Regeneron Pharmaceuticals Inc, and Sanofi. He has served on advisory boards and received honoraria for symposia from Akcea, Amgen, and Sanofi. R.Z, J.H., and M.M. are current employees of Arrowhead Pharmaceuticals, Inc. D.G. received grants or honoraria from Acasti, Akcea, Allergan, Amryt Pharma, Amgen, Applied Therapeutics, Arrowhead, AstraZeneca, Boehringer Ingelheim, Dalcor Pharma, Eli Lilly, Esperion, Institut de Cardiologie de Montréal, Ionis, Kowa, The Medicines Company, NovoNordisk, Pfizer, Regeneron, UniQure, and Verve Therapeutics. N.J.L. has received research funding from the National Institutes of Health, American Heart Association, and Greathouse Foundation. N.J.L. is also cofounder and board director, Bitterroot Bio; unpaid consultant for Arrowhead Pharmaceuticals, Inc; and consultant for Regeneron, Mingsight Pharmaceuticals, and Janssen. The other author reports no conflicts.